 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2022, vol. 28, issue4
Subject Area: Medicine
-
DOI: 10.5272/jimab.2022284.4749
Published online: 19 December 2022
Case report
J of IMAB. 2022 Oct-Dec;28(4):4749-4752
A CURE FOR RECENTLY ACQUIRED HEPATITIS C
Radka Komitova1, 2
, Georgi Kiprin3, Elica Golgocheva-Markova4,
1) Department of Infectious Diseases, Parasitology and Tropical Medicine, Faculty of Medicine, Medical University of Plovdiv, Bulgaria.
2) Department of Infectious Diseases, University Hospital St. George, Plovdiv, Bulgaria.
3) Department of Gastroenterology, University Hospital Eurohospital, Plovdiv, Bulgaria.
4) National Reference Laboratory "Hepatitis viruses", National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
ABSTRACT:
Chronic hepatitis C is a global health threat. Most individuals infected with the hepatitis C virus (HCV) will inevitably progress to chronic infection, leading to cirrhosis and hepatocellular carcinoma. The current use of direct-acting antiviral (DAA) agents has changed the outlook for the treatment resulting in a cure for a short time. Recently acquired hepatitis C, also known as acute hepatitis, should be treated with regimens similar to chronic hepatitis C. We report a case of recently acquired hepatitis C manifested with jaundice, confirmed by a positive HCV RNA result and seroconversion. The patient was referred to a gastroenterologist with his girlfriend with newly diagnosed chronic hepatitis C for further evaluation and treatment. Both underwent DAA treatment with glecaprevir/pibrentasvir for two months. Upon completion of the therapy and 12 weeks later, HCV PCR was undetected in both cases. We treated our patient long before the onset of chronic liver disease and long-term complications. The current case underscores the importance of asking about potential ongoing exposure to an HCV-infected person.
Keywords: Direct-acting antiviral therapy, exposure to an HCV-infected person, early HCV infection, sustained virological response,
- Download FULL TEXT /PDF 500 KB/
Please cite this article as: Komitova R, Kiprin G, Golgocheva-Markova E. A cure for recently acquired hepatitis C. J of IMAB. 2022 Oct-Dec;28(4):4749-4752. DOI: 10.5272/jimab.2022284.4749
Correspondence to: Prof. Radka Komitova, MD, PhD, Department of Infectious Diseases, Medical University, Plovdiv; 15A, Vassil Aprilov Blvd., 4000 Plovdiv, Bulgaria; E-mail: Radka.komitova@yahoo.com
REFERENCES:
1. WHO fact sheets hepatitis C. WHO. 24 June 2022. [Internet]
2. Spearman CW, Dusheiko G, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019 Oct 19:394:1451–66. [PubMed]
3. D'ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol. 2017 Jun;24:31-37. [PubMed]
4. Ingiliz P, WehmeyerMh, Boesecke C, Schulze ZurWiesch J, Schewe K, Lutz T, et al. Reinfection with the hepatitis c virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: current incidence rates, compared with rates during the interferon era. Clin Infect Dis. 2020 22 August; 71(5):1248-1254. [PubMed]
5. Pradat P, Huleux T, Raffi F, Delobel P, Valantin MA, Poizot-Martin I, et al. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS. 2018 May 15;32(8):1077-1082. [PubMed]
6. Price Jc, Mckinney JE, Crouch PC, Dillon Sm, Radix A, Stivala A, et al. Sexually acquired hepatitis C Infection in HIV-uninfected men who have sex with men using preexposure prophylaxis against HIV. J Infect Dis. 2019 16 April; 219(9):1373-1376. [PubMed]
7. Cox Al. Medicine. Global control of hepatitis c virus. Science. 2015 Aug 21;349(6250):790-1. [PubMed]
8. Orland JR, Wright Tl, Cooper S. Acute hepatitis C. Hepatology. 2001 Feb;33(2):321-7. [PubMed]
9. Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol. 2012 Dec;57(6):1349-6. [PubMed]
10. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020 Nov;73(5):1170-218. [PubMed]
11. Consensus Panel. Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. AIDS. 2020 Oct 1;34(12):1699-711. [PubMed]
12. Seeff LB. Natural history of chronic hepatitis.Hepatology. 2002 Nov;36(5 Suppl 1):S35-46. [PubMed]
13. Rossotti R, Puoti M. Sexually transmitted hepatitis. In: Sexually Transmitted Infections. Cristaudo A, Giuliani M, (eds). Springer, Cham. 31 May 2020, pp.255-275. [Crossref]
14. Basu PP, Shah NJ, Aloysius MM, Brown RS Jr. Sofosbuvir and Ledipasvir vs Sofosbuvir and Simeprevir for acute hepatitis C: a RCT (SLAM C study). In: Abstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan. Hepatol Int. 2016; 10(Suppl 1):S14-15. - [Internet]
15. Rockstroh Jk, Bhagani S, Hyland Rh, Yun C, Dvory-Sobol H, Zheng W, et al. Ledipasvir-Sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype1 or 4infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet GastroenterolHepatol. 2017 May;2(5):347-353. [PubMed]
16. Ghany MG, Morgan TR; AASLD-IDSA. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020 Feb;71(2):686-721. [PubMed]
17. Terrault NA, Dodge JL, Murphy El, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013 Mar;57(3):881-9. [PubMed]
18. Matthews GV, Pham St, Hellard M, Grebely J, Zhang L, Oon A, at al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.Clin Infect Dis. 2011 15 March;52(6):803-11. [PubMed]
19. Zeuzem S, Teuber G, Lee Jh, Rьster B, Roth Wk. Risk factors for the transmission of hepatitis C. J Hepatol. 1996;24(2 Suppl):3-10. [PubMed].
Received: 03 May 2022
Published online: 19 December 2022